Portal de Periódicos da CAPES

The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment

2023; Elsevier BV; Volume: 53; Linguagem: Inglês

10.1016/j.athplu.2023.06.001

2667-0909

Winfried März, Nina Schmidt, Ira an Haack, Alexander Dressel, Tanja B. Grammer, Marcus E. Kleber, Andrea Baessler, Frank Ulrich Beil, Ioanna Gouni‐Berthold, Ulrich Julius, Ursula Kassner, Julius L. Katzmann, Gerald Klose, Christel König, Wolfgang Köenig, Ann‐Cathrin Koschker, Ulrich Laufs, Martin Merkel, Britta Otte, Klaus G. Parhofer, Wibke Hengstenberg, Heribert Schunkert, Ksenija Stach-Jablonski, Elisabeth Steinhagen‐Thiessen, Christoph B. Olivier, Harry Hahmann, Stefan Krzossok, Anja Vogt, Dirk Müller‐Wieland, Ulrike Schatz,

Genetic factors in colorectal cancer

Familial hypercholesterolemia (FH) is among the most common genetic disorders in primary care. However, only 15% or less of patients are diagnosed, and few achieve the goals for low-density lipoprotein cholesterol (LDL-C). In this analysis of the German Cascade Screening and Registry for High Cholesterol (CaRe High), we examined the status of lipid management, treatment strategies, and LDL-C goal attainment according to the ESC/EAS dyslipidemia guidelines. We evaluated consolidated datasets from 1501 FH patients diagnosed clinically and seen either by lipid specialists or general practitioners and internists. We conducted a questionnaire survey of both the recruiting physicians and patients. Among the 1501 patients, 86% regularly received lipid-lowering drugs. LDL-C goals were achieved by 26% and 10% of patients with atherosclerotic cardiovascular disease (ASCVD) according to the 2016 and 2019 ESC/EAS dyslipidemia guidelines, respectively. High intensity lipid-lowering was administered more often in men than in women, in patients with ASCVD, at higher LDL-C and in patients with a genetic diagnosis of FH. FH is under-treated in Germany compared to guideline recommendations. Male gender, genetic proof of FH, treatment by a specialist, and presence of ASCVD appear to be associated with increased treatment intensity. Achieving the LDL-C goals of the 2019 ESC/EAS dyslipidemia guidelines remains challenging if pre-treatment LDL-C is very high.